Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Annals of Oncology

Volumn 23, Issue 12, 2012, Pages 3069-3074

  Alba, E ^a   Calvo, L ^b   Albanell, J ^c   De la Haba, J R ^d   Arcusa Lanza, A ^e   Chacon, J I ^f   Sanchez Rovira, P ^c   Plazaola, A ^c   Lopez Garcia Asenjo, J A ^g   Bermejo, B ^h   Carrasco, E ⁱ   Lluch, A ^h  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c H del Mar ^*  (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e Brain   (Spain)

^f HOSPITAL VIRGEN DE LA SALUD   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁱ GEICAM   (Spain)

Author keywords

Chemotherapy; Hormonotherapy; Luminal breast cancer; Neoadjuvant

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; GOSERELIN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LEUKOPENIA; LUMINAL BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84869740457     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds132     Document Type: Article

References (43)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
3. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
4. Perreard L, Fan C, Quackenbush JF et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 2006; 8: R23.
5. Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
6. Oh DS, Troester MA, Usary J et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006; 24: 1656-1664.
7. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
8. Bild AH, Parker JS, Gustafson AM et al. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res 2009; 11: R55.
9. Whitfield ML, George LK, Grant GD et al. Common markers of proliferation. Nat Rev Cancer 2006; 6: 99-106.
10. Snoj N, Bedard PL, de Azambuja E et al. Are we HER-ting for innovation in neoadjuvant breast cancer design? Breast Cancer Res 2009; 11: 201.
11. Berruti A, Brizzi MP, Generali D et al. Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. Oncologist 2008; 13: 1137-1148.
12. Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
13. Chollet P, Amat S, Cure H et al. Prognostic significance of complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86: 1041-1046.
14. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer:significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
15. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
16. Petit T, Wilt M, Velten M et al. Comparative value of tumour grade, hormonal receptors, Ki 67, HER2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Eur J Cancer 2004; 40: 205-211.
17. Bottini A, Berruti A, Brizzi MP et al. Cytotoxic and antiproliferative activity of the single agent epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single institution phase III trial. Endocr Relat Cancer 2005; 12: 383-392.
18. Jones RL, Lakhani SR, Ring AE et al. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 2006; 94: 358-362.
19. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
20. Gianni L, Baselga J, Eiermann W et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009; 20: 2474-2481.
21. Precht LM, Lowe KL, Atwood M et al. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 2010; 4: 362-368.
22. Bhargava R, Beriwal S, Dabbs DJ et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer 2010; 15(116): 1431-1439.
23. De Ronde JJ, Hannemann J, Halfwerk H et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat. 2010; 119: 119-126.
24. Esserman LJ, Berry DA, Cheang MC et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results form the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 657). Breast Cancer Res Treat 2012; 132: 1049-1062.
25. Rouzier R, Perou C, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
26. Parker J, Prat A, Cheang M et al. Breast cancer molecular subtypes predict response to anthracycline/taxane based chemotherapy. San Antonio Breast Cancer Symposium 2009: (abstract 2019): 598s.
27. Barnadas A, Gil M, Sanchez-Rovira P et al. Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anticancer Drugs 2008; 19: 339-347.
28. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long term survival in patients with triple negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
29. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
30. Ogston KN, Miller ID, Payne S et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003;12(5): 320-327.
31. National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) version 3.0. Available at http://ctep.info.nih.gov/reporting/index.html.
32. Chia YH, Ellis MJ, Ma CX. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as research tool. Br J Cancer 2010; 103: 759-764.
33. Early Breast cancer Trials Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
34. Berry D, Cirrincione C, Henderson IC et al. Estrogen receptor status and outcomes of modern chemotherapy in women with node positive breast cancer. JAMA 2006; 295: 1658-1667.
35. Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in node positive breast cancer. N Engl J Med 2007; 357: 1496-1506.
36. Ellis P, Barrett-Lee P, Johnson L et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open label, phase III, randomised controlled trial. Lancet 2009; 373: 1681-1692.
37. Semiglazov VF, Semiglazov VV, Dashyan GA et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007; 110: 244-254.
38. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
39. Nielsen T, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with inmunohistochemistry and clinical prognostic factors in tamoxifen treated estrogen receptor positive breast cancer. Clin Cancer Res 2010; 16: 5222-5232.
40. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14: 5158-5165.
41. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
42. Park IH, Ro J, Lee KS et al. Phase II parrallel group study showing comparable efficacy between metastatic premenopausal breast cancer patients treated with letrozol plus goserelin and postmenopausal patients treated with letrozole alone as first line hormone therapy. J Clin Oncol 2010; 28: 2705-2711.
43. Carlson RW, Theriault R, Schurman CM et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 2010; 28: 3917-3921.